128 related articles for article (PubMed ID: 26894823)
21. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
Connor DF; Rubin J
Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
[TBL] [Abstract][Full Text] [Related]
22. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study.
Singh D; Wakimoto Y; Filangieri C; Pinkhasov A; Angulo M
J Child Adolesc Psychopharmacol; 2019 May; 29(4):313-317. PubMed ID: 30724590
[No Abstract] [Full Text] [Related]
23. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
Newcorn JH; Harpin V; Huss M; Lyne A; Sikirica V; Johnson M; Ramos-Quiroga JA; van Stralen J; Dutray B; Sreckovic S; Bloomfield R; Robertson B
J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
[TBL] [Abstract][Full Text] [Related]
24. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
Sallee FR; Eaton K
Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
[TBL] [Abstract][Full Text] [Related]
25. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
Jain R; Katic A
Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
27. ▼Guanfacine for ADHD in children and adolescents.
Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
[TBL] [Abstract][Full Text] [Related]
28. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
[TBL] [Abstract][Full Text] [Related]
29. Systemic administration of guanfacine improves food-motivated impulsive choice behavior primarily via direct stimulation of postsynaptic α
Nishitomi K; Yano K; Kobayashi M; Jino K; Kano T; Horiguchi N; Shinohara S; Hasegawa M
Behav Brain Res; 2018 Jun; 345():21-29. PubMed ID: 29476896
[TBL] [Abstract][Full Text] [Related]
30. Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies.
Taormina SP; Galloway MP; Rosenberg DR
J Dev Behav Pediatr; 2016; 37(6):491-5. PubMed ID: 27011005
[TBL] [Abstract][Full Text] [Related]
31. Effect on Primary Sleep Disorders When Children With ADHD Are Administered Guanfacine Extended Release.
Rugino TA
J Atten Disord; 2018 Jan; 22(1):14-24. PubMed ID: 25376194
[TBL] [Abstract][Full Text] [Related]
32. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Wigal SB; Chae S; Patel A; Steinberg-Epstein R
Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
[TBL] [Abstract][Full Text] [Related]
33. The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHD.
Pillidge K; Porter AJ; Dudley JA; Tsai YC; Heal DJ; Stanford SC
Br J Pharmacol; 2014 Oct; 171(20):4785-96. PubMed ID: 25074741
[TBL] [Abstract][Full Text] [Related]
34. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
[TBL] [Abstract][Full Text] [Related]
36. Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder.
Doi K; Sogawa R; Eguchi Y; Matsuo M; Shimanoe C
Biol Pharm Bull; 2024; 47(6):1204-1208. PubMed ID: 38910124
[TBL] [Abstract][Full Text] [Related]
37. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
38. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
Posey DJ; Puntney JI; Sasher TM; Kem DL; McDougle CJ
J Child Adolesc Psychopharmacol; 2004; 14(2):233-41. PubMed ID: 15319020
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).
Alamo C; López-Muñoz F; Sánchez-García J
Actas Esp Psiquiatr; 2016 May; 44(3):107-12. PubMed ID: 27254403
[TBL] [Abstract][Full Text] [Related]
40. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
Bukstein OG; Head J
Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
